An analysis of exome sequencing for diagnostic testing of the genes associated with muscle disease and spastic paraplegia

Cristina Dias, Murat Sincan, Praveen F. Cherukuri, Rosemarie Rupps, Yan Huang, Hannah Briemberg, Kathryn Selby, James C. Mullikin, Thomas C. Markello, David R. Adams, William A. Gahl, Cornelius F. Boerkoel

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In this study, we assess exome sequencing (ES) as a diagnostic alternative for genetically heterogeneous disorders. Because ES readily identified a previously reported homozygous mutation in the CAPN3 gene for an individual with an undiagnosed limb girdle muscular dystrophy, we evaluated ES as a generalizable clinical diagnostic tool by assessing the targeting efficiency and sequencing coverage of 88 genes associated with muscle disease (MD) and spastic paraplegia (SPG). We used three exome-capture kits on 125 individuals. Exons constituting each gene were defined using the UCSC and CCDS databases. The three exome-capture kits targeted 47-92% of bases within the UCSC-defined exons and 97-99% of bases within the CCDS-defined exons. An average of 61.2-99.5% and 19.1-99.5% of targeted bases per gene were sequenced to 20X coverage within the CCDS-defined MD and SPG coding exons, respectively. Greater than 95-99% of targeted known mutation positions were sequenced to ≥1X coverage and 55-87% to ≥20X coverage in every exome. We conclude, therefore, that ES is a rapid and efficient first-tier method to screen for mutations, particularly within the CCDS annotated exons, although its application requires disclosure of the extent of coverage for each targeted gene and supplementation with second-tier Sanger sequencing for full coverage.

Original languageEnglish (US)
Pages (from-to)614-626
Number of pages13
JournalHuman mutation
Volume33
Issue number4
DOIs
StatePublished - Apr 1 2012

Fingerprint

Exome
Paraplegia
Muscles
Exons
Genes
Mutation
Limb-Girdle Muscular Dystrophies
Disclosure
Databases

Keywords

  • CAPN3
  • Clinical genetic testing
  • Exome
  • HSP
  • LGMD
  • Neuromuscular disorders

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

An analysis of exome sequencing for diagnostic testing of the genes associated with muscle disease and spastic paraplegia. / Dias, Cristina; Sincan, Murat; Cherukuri, Praveen F.; Rupps, Rosemarie; Huang, Yan; Briemberg, Hannah; Selby, Kathryn; Mullikin, James C.; Markello, Thomas C.; Adams, David R.; Gahl, William A.; Boerkoel, Cornelius F.

In: Human mutation, Vol. 33, No. 4, 01.04.2012, p. 614-626.

Research output: Contribution to journalArticle

Dias, C, Sincan, M, Cherukuri, PF, Rupps, R, Huang, Y, Briemberg, H, Selby, K, Mullikin, JC, Markello, TC, Adams, DR, Gahl, WA & Boerkoel, CF 2012, 'An analysis of exome sequencing for diagnostic testing of the genes associated with muscle disease and spastic paraplegia', Human mutation, vol. 33, no. 4, pp. 614-626. https://doi.org/10.1002/humu.22032
Dias, Cristina ; Sincan, Murat ; Cherukuri, Praveen F. ; Rupps, Rosemarie ; Huang, Yan ; Briemberg, Hannah ; Selby, Kathryn ; Mullikin, James C. ; Markello, Thomas C. ; Adams, David R. ; Gahl, William A. ; Boerkoel, Cornelius F. / An analysis of exome sequencing for diagnostic testing of the genes associated with muscle disease and spastic paraplegia. In: Human mutation. 2012 ; Vol. 33, No. 4. pp. 614-626.
@article{bf78f500d442491e89e8f422dfdb53d9,
title = "An analysis of exome sequencing for diagnostic testing of the genes associated with muscle disease and spastic paraplegia",
abstract = "In this study, we assess exome sequencing (ES) as a diagnostic alternative for genetically heterogeneous disorders. Because ES readily identified a previously reported homozygous mutation in the CAPN3 gene for an individual with an undiagnosed limb girdle muscular dystrophy, we evaluated ES as a generalizable clinical diagnostic tool by assessing the targeting efficiency and sequencing coverage of 88 genes associated with muscle disease (MD) and spastic paraplegia (SPG). We used three exome-capture kits on 125 individuals. Exons constituting each gene were defined using the UCSC and CCDS databases. The three exome-capture kits targeted 47-92{\%} of bases within the UCSC-defined exons and 97-99{\%} of bases within the CCDS-defined exons. An average of 61.2-99.5{\%} and 19.1-99.5{\%} of targeted bases per gene were sequenced to 20X coverage within the CCDS-defined MD and SPG coding exons, respectively. Greater than 95-99{\%} of targeted known mutation positions were sequenced to ≥1X coverage and 55-87{\%} to ≥20X coverage in every exome. We conclude, therefore, that ES is a rapid and efficient first-tier method to screen for mutations, particularly within the CCDS annotated exons, although its application requires disclosure of the extent of coverage for each targeted gene and supplementation with second-tier Sanger sequencing for full coverage.",
keywords = "CAPN3, Clinical genetic testing, Exome, HSP, LGMD, Neuromuscular disorders",
author = "Cristina Dias and Murat Sincan and Cherukuri, {Praveen F.} and Rosemarie Rupps and Yan Huang and Hannah Briemberg and Kathryn Selby and Mullikin, {James C.} and Markello, {Thomas C.} and Adams, {David R.} and Gahl, {William A.} and Boerkoel, {Cornelius F.}",
year = "2012",
month = "4",
day = "1",
doi = "10.1002/humu.22032",
language = "English (US)",
volume = "33",
pages = "614--626",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - An analysis of exome sequencing for diagnostic testing of the genes associated with muscle disease and spastic paraplegia

AU - Dias, Cristina

AU - Sincan, Murat

AU - Cherukuri, Praveen F.

AU - Rupps, Rosemarie

AU - Huang, Yan

AU - Briemberg, Hannah

AU - Selby, Kathryn

AU - Mullikin, James C.

AU - Markello, Thomas C.

AU - Adams, David R.

AU - Gahl, William A.

AU - Boerkoel, Cornelius F.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - In this study, we assess exome sequencing (ES) as a diagnostic alternative for genetically heterogeneous disorders. Because ES readily identified a previously reported homozygous mutation in the CAPN3 gene for an individual with an undiagnosed limb girdle muscular dystrophy, we evaluated ES as a generalizable clinical diagnostic tool by assessing the targeting efficiency and sequencing coverage of 88 genes associated with muscle disease (MD) and spastic paraplegia (SPG). We used three exome-capture kits on 125 individuals. Exons constituting each gene were defined using the UCSC and CCDS databases. The three exome-capture kits targeted 47-92% of bases within the UCSC-defined exons and 97-99% of bases within the CCDS-defined exons. An average of 61.2-99.5% and 19.1-99.5% of targeted bases per gene were sequenced to 20X coverage within the CCDS-defined MD and SPG coding exons, respectively. Greater than 95-99% of targeted known mutation positions were sequenced to ≥1X coverage and 55-87% to ≥20X coverage in every exome. We conclude, therefore, that ES is a rapid and efficient first-tier method to screen for mutations, particularly within the CCDS annotated exons, although its application requires disclosure of the extent of coverage for each targeted gene and supplementation with second-tier Sanger sequencing for full coverage.

AB - In this study, we assess exome sequencing (ES) as a diagnostic alternative for genetically heterogeneous disorders. Because ES readily identified a previously reported homozygous mutation in the CAPN3 gene for an individual with an undiagnosed limb girdle muscular dystrophy, we evaluated ES as a generalizable clinical diagnostic tool by assessing the targeting efficiency and sequencing coverage of 88 genes associated with muscle disease (MD) and spastic paraplegia (SPG). We used three exome-capture kits on 125 individuals. Exons constituting each gene were defined using the UCSC and CCDS databases. The three exome-capture kits targeted 47-92% of bases within the UCSC-defined exons and 97-99% of bases within the CCDS-defined exons. An average of 61.2-99.5% and 19.1-99.5% of targeted bases per gene were sequenced to 20X coverage within the CCDS-defined MD and SPG coding exons, respectively. Greater than 95-99% of targeted known mutation positions were sequenced to ≥1X coverage and 55-87% to ≥20X coverage in every exome. We conclude, therefore, that ES is a rapid and efficient first-tier method to screen for mutations, particularly within the CCDS annotated exons, although its application requires disclosure of the extent of coverage for each targeted gene and supplementation with second-tier Sanger sequencing for full coverage.

KW - CAPN3

KW - Clinical genetic testing

KW - Exome

KW - HSP

KW - LGMD

KW - Neuromuscular disorders

UR - http://www.scopus.com/inward/record.url?scp=84862777349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862777349&partnerID=8YFLogxK

U2 - 10.1002/humu.22032

DO - 10.1002/humu.22032

M3 - Article

C2 - 22311686

AN - SCOPUS:84862777349

VL - 33

SP - 614

EP - 626

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 4

ER -